Board of Directors

Jean-François MOUNEY co-founded GENFIT in 1999 after having been actively involved in the incubation of the Company from 1997. Prior to this, he had created, managed and developed several companies specializing in high-performance materials, particularly in the aeronautical industry, since 1979. In 1992, he founded M&M, a consultancy firm specializing in health economics. He was responsible for carrying out a feasibility study for an economic development agency within the field of health and biology in the Nord-Pas-de-Calais region of France and was appointed Chief Executive Officer of this agency since its launch in 1995. Over a hundred companies have been created as part of this venture, making Eurasanté one of the top European bioincubators and clusters. As Chairman of the Executive Board of GENFIT, he received, in 2003, the Entrepreneur of the Year award, which is organized internationally by Ernst & Young, in the New Technology category. He also received this award in 2004. In September 2017, when Genfit's legal structure changed, he became Chief Executive Officer of the Company until September 2019, when he stepped down to focus on his role as Chairman of the Board of Directors. Jean-François MOUNEY was also Advisor to the Banque de France from 2008 to 2023. He graduated from the ESCP Europe business school and has a Masters in Economic from the University of Lille.

Mr. Éric BACLET has extensive management experience gained at the American pharmaceutical group Lilly over a period of 30 years, during which he held numerous management positions at the head of diverse, multicultural international teams involved in all stages of the value chain. His many responsibilities covered the development and marketing strategy for many of the group's flagship brands, as well as its neuroscience portfolio. Mr. Éric BACLET has also served as CEO of several of the group's subsidiaries, notably in North Africa, Belgium, China, Italy, and Eastern Europe. He has a strong track record of financial results, a transformation agenda focused on customer experience, and a high level of integrity. Mr. Éric Baclet holds a degree in Pharmacy from René Descartes University.

Since September 2020, Dr. Catherine LARUE has been running CoDx, a consulting firm specializing in biotechnology and medical diagnostics. Previously, from 2012 to 2020, she was CEO of IBBL (Integrated BioBank of Luxembourg), where she was involved in developing the biobank's strategy and new initiatives related to personalized medicine. During this time, she also served as interim CEO of the Luxembourg Institute of Health (LIH), the Luxembourg Biomedical Research Institute, for nearly two years. Before joining IBBL, Dr. Catherine LARUE led the “Biomarkers” program at GENFIT until 2012. Dr. Catherine LARUE began her career as a Team Leader at Sanofi in R&D in the Cardiovascular Research Department. She then joined Sanofi Diagnostics Pasteur, where she worked as R&D Director in France and the US, before spending 11 years with the Bio-Rad group, where she held various management positions. She has been involved in the discovery of several innovative biomarkers and the marketing of dozens of diagnostic products. Dr. Catherine Larue holds a PhD in experimental biology and a Habilitation à Diriger la Recherche (HDR) from the University of Rouen, a university degree in clinical oncology (University of Paris VI), and an Executive MBA (ISM-St. John's University, New York). She was recently certified in the CSRD directive.

Certified IFA Science Po administrator in 2014, certified public accountant in 2008, Ms. MONSELLATO also holds a degree in business management from EM Lyon (1990) and a certificate in “Governance, Climate, and Sustainable Transformation” from Paris Dauphine-PSL University (2024). From May 2015 to March 2023, Anne-Hélène MONSELLATO was an independent member of the Supervisory Board and Chair of the Audit and Risk Committee of Euronav, a Belgian company that is one of the world leaders in the maritime transport of petroleum products, listed on the regulated market of Euronext in Brussels and on the NYSE. She was also Vice-Chair and Treasurer of the Board of Trustees of the American Center for Art and Culture, an American foundation based in New York, from 2014 until its strategic reorientation and dissolution in 2024. Ms. MONSELLATO joined Ernst & Young (now EY) in 1990, where she was a partner from 2005 to 2013. Through this career path, she has acquired extensive experience in financial communication, IFRS standards, cross-border listing operations, particularly in the United States, internal control and risk management, as well as account auditing and internal control over financial reporting. She has worked with several companies in the pharmaceutical and biotechnology sectors. Ms. MONSELLATO has been an active member of the IFA (Institut Français des Administrateurs) since 2013, particularly within the Audit Committee Chairpersons' Club, the ESG Club, and the Prospective Commission (where she has contributed to numerous publications), as well as ecoDa, the European Confederation of Institutes of Directors. She was also a member of the ESMA Corporate Reporting Standing Committee Advisory Working Group from 2019 to 2020, and of the EFRAG Working Group on the development of ESG standards for mid-sized listed companies.

Biotech Avenir Biotech Avenir SAS is a management holding company incorporated in 2001 by the Company's founders. Most of its share capital is currently held by individuals, i.e. the co-founders of the Company and twelve Company employees. Jean-François Mouney, the Chairman of the Board of Directors of the Company, is also the Chairman of the Management Committee of Biotech Avenir SAS. John Brozek John BROZEK holds three master’s degrees respectively in Cell and Molecular Biology from Lille University, Bioinformatics from Paris 7 University and Information Technology from Amiens University. He started his career in 2001 as Bioinformatician with IT-omics, a startup specializing in Information Systems design and data mining for biotech companies. In 2005, he joined GENFIT where he progressively took the lead of In Silico activities providing support in bioinformatics, biostatistics and Information Systems design. Since 2016, in addition to managing the In Silico activities, he leads the IT Department where he has been focusing on a global Information System renewal project while continuing to develop data related project (data science and business intelligence).

Katherine KALIN has over 25 years of experience in the healthcare industry, including 15 years in senior management positions at two leading healthcare companies, where she worked in marketing, sales, strategy, and business development, at Johnson & Johnson from 2002 to 2011 and at Celgene from 2012 to 2017. Before joining Johnson & Johnson, Ms. KALIN was a Partner at McKinsey & Company, where she negotiated and led consulting assignments in the healthcare field, as a strategic advisor to major pharmaceutical and medical device companies, from 1990 through 2002. She began her career in corporate finance at the investment bank Nomura. Ms. KALIN's experience also includes non-executive roles, notably as a director of Sellas Life Sciences, a biopharmaceutical company, FemHealth Ventures, a venture capital firm specializing in women's health, and Brown Advisory, a strategic and investment consulting firm. Ms. KALIN has lived in Asia, Europe, and the United States and has significant international experience gained at the following companies: Nomura International Limited (Tokyo and London), McKinsey & Company Inc. (London, New York, and New Jersey), Johnson & Johnson (New Jersey), and Celgene (New Jersey). Katherine KALIN holds a Bachelor of Arts degree from Durham University in the United Kingdom and an MBA from Harvard Business School.

Until June 2022, Jean-François TINÉ was a senior executive in investment banking. He served as Chairman of the Primary Equity Market within Natixis's Wholesale Banking division, a position to which he was appointed in 2017. Prior to this appointment, he had been Global Head of Natixis's Primary Equity Market since 2005. He began his career in various sales, trading, and syndication roles in the markets in London and Paris, notably at Union Bancaire Privée, Credit Suisse First Boston, and Bank of America. In 1993, he became a partner at MC Securities in London, before being appointed global head of syndication at Société Générale in Paris three years later.

Sandra SILVESTRI, M.D., Ph.D., joined Ipsen in 2023 as Executive Vice President, Chief Medical Officer, Head of Global Medical Affairs and Pharmacovigilance. Prior to joining Ipsen, Dr. SILVESTRI held several senior positions at Sanofi, most recently as Senior Vice President, Chief Medical Officer of the Global General Medicine business unit, leading a team of 1,600 medical staff in various countries. She also held several management positions at Eli Lilly in various therapeutic areas, including diabetes, endocrinology, neuroscience, immunology, dermatology, and oncology. Sandra SILVESTRI is a physician specializing in endocrinology and metabolic diseases. As an investigator in several clinical studies, she has published numerous book chapters and scientific articles in international journals. Sandra SILVESTRI has been a speaker at national and international conferences and, from 2017 to 2023, she chaired Sanofi's Gender Balance Board and Global Network. She teaches at the medical schools of the University of Florence, Italy, and Descartes University in Paris. Sandra SILVESTRI has lived in Italy, Denmark, the United States, and France, and speaks Italian, English, and French.

Mr Tristan IMBERT is Deputy CFO of the Swiss company, Oculis SA. He is an experienced CFO with over 18 years' experience in finance, 10 years in R&D, and 7 years in strategic roles. Mr. Tristan IMBERT began his career at Sanofi Aventis in the R&D function and was based in France, the UK and the USA (1989-2000). In 2000 he joined the consulting firm BCG. Based between Paris and New York, he worked with clients in the pharmaceutical industry. In 2005, Tristan IMBERT joined Novartis and was appointed Head of Strategic Planning in Basel. He progressed within the Group in the finance function and became CFO Nordic Countries and then CFO Canada. In 2018, he was promoted to CFO of Novartis Gene Therapies. After three and a half years in this role, he joined biotech Cimeio Therapeutics in 2021, as CFO, and prepared the company for a potential IPO and new financing round. Mr. Tristan IMBERT left Cimieo Therapeutics in 2024 and no longer has an operational role. He worked in North America (Canada and the United States) and Europe (France, Switzerland, Sweden, and the United Kingdom) in international and multicultural environments. Tristan IMBERT holds a Master's degree in applied mathematics from the Université de Paris-Sud and an MBA from Columbia University-Graduate School of Business in New York.